NasdaqGS - Delayed Quote • USD
Y-mAbs Therapeutics, Inc. (YMAB)
At close: April 23 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 4 | 6 | 5 |
| Avg. Estimate | -0.14 | -0.12 | -0.46 | -0.28 |
| Low Estimate | -0.18 | -0.18 | -0.73 | -0.8 |
| High Estimate | -0.11 | -0.08 | -0.34 | 0.02 |
| Year Ago EPS | -0.15 | -0.14 | -0.49 | -0.46 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 7 | 6 |
| Avg. Estimate | 22.22M | 23.96M | 97.16M | 118.27M |
| Low Estimate | 21.45M | 23.73M | 95.46M | 110.4M |
| High Estimate | 23.23M | 24.4M | 99.6M | 133M |
| Year Ago Sales | 20.25M | 20.75M | 84.82M | 97.16M |
| Sales Growth (year/est) | 9.70% | 15.50% | 14.50% | 21.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.32 | -0.24 | -0.19 | -0.2 |
| EPS Actual | -0.15 | -0.14 | -0.18 | -0.02 |
| Difference | 0.17 | 0.1 | 0.01 | 0.18 |
| Surprise % | 53.10% | 41.70% | 5.30% | 90.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.14 | -0.12 | -0.46 | -0.28 |
| 7 Days Ago | -0.14 | -0.12 | -0.46 | -0.34 |
| 30 Days Ago | -0.14 | -0.12 | -0.46 | -0.34 |
| 60 Days Ago | -0.2 | -0.22 | -0.78 | -0.89 |
| 90 Days Ago | -0.2 | -0.22 | -0.71 | -0.83 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | YMAB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 6.70% | -- | -- | 0.30% |
| Next Qtr. | 14.30% | -- | -- | 9.80% |
| Current Year | 6.10% | -- | -- | 4.50% |
| Next Year | 39.10% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -88.60% | -- | -- | 11.06% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/6/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 3/4/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 3/4/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2023 |
| Maintains | JP Morgan: Underweight to Underweight | 8/22/2023 |
Related Tickers
ERAS Erasca, Inc.
1.9300
+4.32%
MRUS Merus N.V.
40.82
+0.91%
REPL Replimune Group, Inc.
6.42
0.00%
SRRK Scholar Rock Holding Corporation
14.79
+5.64%
BCYC Bicycle Therapeutics plc
22.68
+0.49%
STRO Sutro Biopharma, Inc.
3.7200
-1.33%
KURA Kura Oncology, Inc.
18.73
+2.97%
LVTX LAVA Therapeutics N.V.
2.9800
+4.56%
CYTK Cytokinetics, Incorporated
65.57
-1.09%
IGMS IGM Biosciences, Inc.
7.70
+14.07%